Roche Cancer Drug Shows Promise in Trials

 

Divarasib, a next-generation KRAS G12C inhibitor by Roche/Genentech, outperforms its competitors (like Amgen's Lumakras and Bristol Myers Squibb's Krazati) primarily by offering greater potency, better selectivity, and significantly improved survival outcomes in non-small cell lung cancer (NSCLC).

 

Divarasib's superiority is backed by landmark head-to-head trial data:

•           Superior Survival Rates: In the Phase III Krascendo-1 trial, divarasib achieved statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to first-generation approved inhibitors.

 

•     Greater Potency and Selectivity: Preclinical studies indicate that divarasib locks the KRAS G12C protein in an inactive ("off") state more effectively than previous-generation treatments, successfully halting tumor-driving signaling.

 

•           Manageable Safety Profile: Despite its stronger efficacy, divarasib does not introduce new safety concerns; its side effect profile remains comparable to older treatments and is considered "manageable and reversible".

 

The WSJ vaguely but enthusiastically describes the clinical trial results:

 

“Roche Holding said a drug candidate showed better potential than existing therapies in a late-stage study with patients with a type of advanced lung cancer who had been previously treated.

 

The Swiss drugmaker said Thursday that its experimental drug, divarasib, met its primary and key secondary objectives in a head-to-head clinical trial that compared it against approved treatments Amgen's Lumakras and Mirati Therapeutics's Krazati.

 

Divarasib showed meaningful improvements in both patients' overall survival and the time they survived without the disease worsening, Roche said. No new safety signals were identified, it added.

 

Roche said it would submit the data to health authorities with the aim of launching the treatment as soon as possible.” [1]

 

1. Business News: Roche Cancer Drug Shows Promise in Trials. Calatayud, Adria.  Wall Street Journal, Eastern edition; New York, N.Y.. 03 July 2026: B3.